135 related articles for article (PubMed ID: 38240078)
41. Is Bcl-2 a predictive marker of neoadjuvant chemotherapy response in patients with urothelial bladder cancer undergoing radical cystectomy?
Turker P; Segersten U; Malmström PU; Hemdan T
Scand J Urol; 2019 Feb; 53(1):45-50. PubMed ID: 30806186
[No Abstract] [Full Text] [Related]
42. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
Tabayoyong W; Li R; Gao J; Kamat A
Urol Clin North Am; 2018 May; 45(2):155-167. PubMed ID: 29650132
[TBL] [Abstract][Full Text] [Related]
43. The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.
Parker WP; Ho PL; Melquist JJ; Scott K; Holzbeierlein JM; Lopez-Corona E; Kamat AM; Lee EK
J Urol; 2015 May; 193(5):1494-9. PubMed ID: 25451834
[TBL] [Abstract][Full Text] [Related]
44. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Herr HW
Eur Urol; 2008 Jul; 54(1):126-32. PubMed ID: 18248875
[TBL] [Abstract][Full Text] [Related]
45. The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study.
Gandaglia G; Popa I; Abdollah F; Schiffmann J; Shariat SF; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI; Sun M
Eur Urol; 2014 Sep; 66(3):561-8. PubMed ID: 24486024
[TBL] [Abstract][Full Text] [Related]
46. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
[No Abstract] [Full Text] [Related]
47. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation.
Sternberg CN
Semin Oncol; 2007 Apr; 34(2):122-8. PubMed ID: 17382795
[TBL] [Abstract][Full Text] [Related]
48. Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer.
Ohyama C; Hatakeyama S; Yoneyama T; Koie T
Int J Urol; 2014 Jan; 21(1):3-4. PubMed ID: 24033445
[No Abstract] [Full Text] [Related]
49. The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
Lenis AT; Fero KE; Ojeaburu L; Lec PM; Golla V; Brisbane W; Leapman MS; Chamie K
Urol Oncol; 2021 Aug; 39(8):496.e17-496.e24. PubMed ID: 33640225
[TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
Osanto S; Álvarez Gómez de Segura C
Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
[TBL] [Abstract][Full Text] [Related]
51. Trends and appropriateness of perioperative chemotherapy for muscle-invasive bladder cancer.
Macleod LC; Yabes JG; Yu M; Fam MM; Hale NE; Turner RM; Lopa SH; Gingrich JR; Borza T; Skolarus TA; Davies BJ; Jacobs BL
Urol Oncol; 2019 Jul; 37(7):462-469. PubMed ID: 31053530
[TBL] [Abstract][Full Text] [Related]
52. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
[TBL] [Abstract][Full Text] [Related]
53. Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long term results.
Bamias A; Deliveliotis C; Karayiannis A; Varkarakis I; Zervas I; Pantazopoulos D; Gika D; Dimopoulos MA
Eur Urol; 2004 Sep; 46(3):344-50; discussion 350-1. PubMed ID: 15306106
[TBL] [Abstract][Full Text] [Related]
54. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
[TBL] [Abstract][Full Text] [Related]
55. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
[TBL] [Abstract][Full Text] [Related]
56. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.
Culp SH; Dickstein RJ; Grossman HB; Pretzsch SM; Porten S; Daneshmand S; Cai J; Groshen S; Siefker-Radtke A; Millikan RE; Czerniak B; Navai N; Wszolek MF; Kamat AM; Dinney CP
J Urol; 2014 Jan; 191(1):40-7. PubMed ID: 23911605
[TBL] [Abstract][Full Text] [Related]
57. A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013-2019.
Körner SK; Jensen JB
Scand J Urol; 2022 Feb; 56(1):34-38. PubMed ID: 34775886
[TBL] [Abstract][Full Text] [Related]
58. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
Koie T; Ohyama C; Hashimoto Y; Hatakeyama S; Yamamoto H; Yoneyama T; Kamimura N
Int J Clin Oncol; 2013 Aug; 18(4):724-30. PubMed ID: 23011100
[TBL] [Abstract][Full Text] [Related]
59. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
60. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging.
Audenet F; Sfakianos JP; Waingankar N; Ruel NH; Galsky MD; Yuh BE; Gin GE
Urol Oncol; 2019 Feb; 37(2):116-122. PubMed ID: 30509868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]